What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Sell
5
OLMA Quote, Financials, Valuation and Earnings
Last price:
$4.21
Seasonality move
:
11.81%
Day range:
$4.19 - $4.45
52-week range:
$3.94 - $16.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.70x
Volume:
531.1K
Avg. volume:
916.5K
1-year change:
-61.8%
Market cap:
$286.3M
Revenue:
--
EPS (TTM):
-$2.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals
|
-- | $0.17 | -- | -5.36% | $26.00 |
|
LFWD
Lifeward
|
$7.8M | -$0.33 | 21.74% | -54.8% | $9.00 |
|
NBY
NovaBay Pharmaceuticals
|
$2.5M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
PTCT
PTC Therapeutics
|
$249M | -$0.65 | 119.66% | -34.58% | $64.93 |
|
PTN
Palatin Technologies
|
-- | -$0.42 | -100% | -67.93% | $7.00 |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals
|
$4.19 | $26.00 | $286.3M | -- | $0.00 | 0% | -- |
|
LFWD
Lifeward
|
$1.83 | $9.00 | $19.5M | -- | $0.00 | 0% | 0.62x |
|
NBY
NovaBay Pharmaceuticals
|
$0.61 | $0.85 | $3M | -- | $0.00 | 0% | 0.06x |
|
PTCT
PTC Therapeutics
|
$56.27 | $64.93 | $4.4B | -- | $0.00 | 0% | 5.36x |
|
PTN
Palatin Technologies
|
$0.78 | $7.00 | $20.3M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.23 | $6.00 | $3.4M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals
|
-- | 2.115 | -- | -- |
|
LFWD
Lifeward
|
-- | -0.377 | -- | 1.25x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.646 | 1.51% | 0.75x |
|
PTCT
PTC Therapeutics
|
186.52% | -0.744 | 67.49% | 2.23x |
|
PTN
Palatin Technologies
|
-- | -1.737 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -2.868 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals
|
-- | -$36.8M | -- | -- | -- | -$26.3M |
|
LFWD
Lifeward
|
$1.8M | -$5.4M | -81.96% | -81.96% | -72.02% | -$4M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PTCT
PTC Therapeutics
|
$196.9M | -$15.9M | -382.54% | -- | -25.16% | -$36.5M |
|
PTN
Palatin Technologies
|
-- | -$5.1M | -- | -- | -2356.3% | -$4.8M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Olema Pharmaceuticals vs. Competitors
-
Which has Higher Returns OLMA or LFWD?
Lifeward has a net margin of -- compared to Olema Pharmaceuticals's net margin of -202.49%. Olema Pharmaceuticals's return on equity of -- beat Lifeward's return on equity of -81.96%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals-- -$0.40 -- LFWDLifeward24.44% -$1.73 $18.8M -
What do Analysts Say About OLMA or LFWD?
Olema Pharmaceuticals has a consensus price target of $26.00, signalling upside risk potential of 520.53%. On the other hand Lifeward has an analysts' consensus of $9.00 which suggests that it could grow by 391.8%. Given that Olema Pharmaceuticals has higher upside potential than Lifeward, analysts believe Olema Pharmaceuticals is more attractive than Lifeward.
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals5 0 0 LFWDLifeward1 0 0 -
Is OLMA or LFWD More Risky?
Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lifeward has a beta of 1.732, suggesting its more volatile than the S&P 500 by 73.212%.
-
Which is a Better Dividend Stock OLMA or LFWD?
Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifeward offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. Lifeward pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or LFWD?
Olema Pharmaceuticals quarterly revenues are --, which are smaller than Lifeward quarterly revenues of $7.5M. Olema Pharmaceuticals's net income of -$33.6M is lower than Lifeward's net income of -$15.3M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while Lifeward's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus 0.62x for Lifeward. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals-- -- -- -$33.6M LFWDLifeward0.62x -- $7.5M -$15.3M
-
Which has Higher Returns OLMA or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Olema Pharmaceuticals's net margin of -49.65%. Olema Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals-- -$0.40 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About OLMA or NBY?
Olema Pharmaceuticals has a consensus price target of $26.00, signalling upside risk potential of 520.53%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 39.34%. Given that Olema Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Olema Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals5 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is OLMA or NBY More Risky?
Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.
-
Which is a Better Dividend Stock OLMA or NBY?
Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or NBY?
Olema Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Olema Pharmaceuticals's net income of -$33.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals-- -- -- -$33.6M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns OLMA or PTCT?
PTC Therapeutics has a net margin of -- compared to Olema Pharmaceuticals's net margin of -30.91%. Olema Pharmaceuticals's return on equity of -- beat PTC Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals-- -$0.40 -- PTCTPTC Therapeutics92.36% -$0.85 $1.3B -
What do Analysts Say About OLMA or PTCT?
Olema Pharmaceuticals has a consensus price target of $26.00, signalling upside risk potential of 520.53%. On the other hand PTC Therapeutics has an analysts' consensus of $64.93 which suggests that it could grow by 15.39%. Given that Olema Pharmaceuticals has higher upside potential than PTC Therapeutics, analysts believe Olema Pharmaceuticals is more attractive than PTC Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals5 0 0 PTCTPTC Therapeutics6 4 1 -
Is OLMA or PTCT More Risky?
Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.660, suggesting its less volatile than the S&P 500 by 34.007%.
-
Which is a Better Dividend Stock OLMA or PTCT?
Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or PTCT?
Olema Pharmaceuticals quarterly revenues are --, which are smaller than PTC Therapeutics quarterly revenues of $213.2M. Olema Pharmaceuticals's net income of -$33.6M is higher than PTC Therapeutics's net income of -$65.9M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus 5.36x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals-- -- -- -$33.6M PTCTPTC Therapeutics5.36x -- $213.2M -$65.9M
-
Which has Higher Returns OLMA or PTN?
Palatin Technologies has a net margin of -- compared to Olema Pharmaceuticals's net margin of -2357.27%. Olema Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals-- -$0.40 -- PTNPalatin Technologies-- -$0.12 -$111.5K -
What do Analysts Say About OLMA or PTN?
Olema Pharmaceuticals has a consensus price target of $26.00, signalling upside risk potential of 520.53%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 796.52%. Given that Palatin Technologies has higher upside potential than Olema Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Olema Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals5 0 0 PTNPalatin Technologies0 0 0 -
Is OLMA or PTN More Risky?
Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.
-
Which is a Better Dividend Stock OLMA or PTN?
Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or PTN?
Olema Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Olema Pharmaceuticals's net income of -$33.6M is lower than Palatin Technologies's net income of -$2.4M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals-- -- -- -$33.6M PTNPalatin Technologies-- -- $350K -$2.4M
-
Which has Higher Returns OLMA or TOVX?
Theriva Biologics has a net margin of -- compared to Olema Pharmaceuticals's net margin of --. Olema Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals-- -$0.40 -- TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About OLMA or TOVX?
Olema Pharmaceuticals has a consensus price target of $26.00, signalling upside risk potential of 520.53%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 387.81%. Given that Olema Pharmaceuticals has higher upside potential than Theriva Biologics, analysts believe Olema Pharmaceuticals is more attractive than Theriva Biologics.
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals5 0 0 TOVXTheriva Biologics0 0 0 -
Is OLMA or TOVX More Risky?
Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.
-
Which is a Better Dividend Stock OLMA or TOVX?
Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or TOVX?
Olema Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Olema Pharmaceuticals's net income of -$33.6M is lower than Theriva Biologics's net income of -$4.4M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals-- -- -- -$33.6M TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
29
UNF alert for Mar 26
UniFirst [UNF] is up 0.05% over the past day.
Sell
30
KEQU alert for Mar 26
Kewaunee Scientific [KEQU] is up 1.01% over the past day.
Buy
82
EPAC alert for Mar 26
Enerpac Tool Group [EPAC] is down 0.53% over the past day.
